top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

G. Doug Iiekking net worth and biography

G. Iiekking Biography and Net Worth

CFO of USANA Health Sciences

G. Douglas Hekking was promoted from Executive Vice President of Finance, a position that he has held since May 2016, to Chief Financial Officer in May 2017. Mr. Hekking joined USANA in 1992 and served in several management positions until March 1996, when he was appointed as Controller. Mr. Hekking served as Controller from March 1996 until February 2005, when he was appointed as Vice President of Finance. He served as Vice President of Finance until July 2007, when he transitioned to our operations group and was appointed as Executive Director of Special Projects. He served in this position until May 2011, when he was promoted to Chief Financial Officer. Mr. Hekking served in this role until December 2012, when he stepped aside to attend to certain family health matters. In December 2012, Mr. Hekking was appointed as Vice President of Finance until May 2016, when he was appointed as Executive Vice President of Finance. Mr. Hekking received a B.S. in accounting from the University of Utah and an M.B.A. from Brigham Young University.

What is G. Doug Iiekking's net worth?: The estimated net worth of G. Doug Iiekking is at least $80,247.08 as of August 1st, 2022. Mr. Iiekking owns 1,838 shares of USANA Health Sciences stock worth more than $80,247 as of April 25th. This net worth evaluation does not reflect any other assets that Mr. Iiekking may own. Learn More about G. Doug Iiekking's net worth.
How do I contact G. Doug Iiekking?: The corporate mailing address for Mr. Iiekking and other USANA Health Sciences executives is 3838 West Parkway Blvd, Salt Lake City UT, 84120. USANA Health Sciences can also be reached via phone at (801) 954-7100 and via email at [email protected]. Learn More on G. Doug Iiekking's contact information.
Has G. Doug Iiekking been buying or selling shares of USANA Health Sciences?: G. Doug Iiekking has not been actively trading shares of USANA Health Sciences in the last ninety days. Most recently, G Doug Iiekking sold 1,086 shares of the business's stock in a transaction on Monday, August 1st. The shares were sold at an average price of $70.51, for a transaction totalling $76,573.86. Following the completion of the sale, the chief financial officer now directly owns 1,838 shares of the company's stock, valued at $129,597.38. Learn More on G. Doug Iiekking's trading history.
Who are USANA Health Sciences' active insiders?: USANA Health Sciences' insider roster includes Robert Auciaux (Director), Jim Brown (President), John Fleming (Director), Joshua Foukas (Insider), Gilbert Fuller (Director), G. Iiekking (CFO), Daniel Macuga (Insider), David Mulham (Insider), Brent Neidig (Insider), Walter Noot (COO), Feng Peng (Director), Robert Sinnott (Insider), Myron Wentz (Major Shareholder), and Frederic Winssinger (Director). Learn More on USANA Health Sciences' active insiders.
Are insiders buying or selling shares of USANA Health Sciences?: In the last twelve months, insiders at the sold shares 20 times. They sold a total of 59,164 shares worth more than $3,449,714.61. The most recent insider tranaction occured on March, 11th when Chairman Kevin Guest sold 11,011 shares worth more than $539,539.00. Insiders at USANA Health Sciences own 0.3% of the company. Learn More about insider trades at USANA Health Sciences.
Information on this page was last updated on 3/11/2024.

G. Doug Iiekking Insider Trading History at USANA Health Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/1/2022	Sell	1,086	$70.51	$76,573.86	1,838
11/5/2021	Sell	219	$103.48	$22,662.12
2/11/2021	Sell	3,728	$95.02	$354,234.56	1,403
11/4/2020	Sell	454	$76.29	$34,635.66	1,913
2/10/2020	Sell	2,259	$83.44	$188,490.96	3,654
2/6/2020	Sell	1,395	$78.65	$109,716.75	3,654
10/25/2019	Sell	1,746	$75.33	$131,526.18	2,032
10/29/2018	Sell	387	$111.85	$43,285.95
9/6/2018	Sell	6,570	$126.25	$829,462.50	2,200
9/4/2018	Sell	2,200	$130.08	$286,176.00	2,200
5/2/2018	Sell	510	$105.54	$53,825.40
3/7/2018	Sell	2,423	$81.05	$196,384.15	2,423

G. Doug Iiekking Buying and Selling Activity at USANA Health Sciences

USANA Health Sciences Company Overview

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products through retail stores and online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.

Today's Range

Now: $43.66

$43.37

$44.67

50 Day Range

MA: $47.42

$43.01

$50.17

2 Week Range

Now: $43.66

$42.59

$69.60

Volume

89,431 shs

Average Volume

81,869 shs

Market Capitalization

$840.02 million

P/E Ratio

13.23

Dividend Yield

N/A

Beta

0.91